Diagnostic ability of spectral CT-based vertebral hydroxyapatite concentration for bone mineral density assessment in patients with liver cirrhosis: evaluating in unenhanced, arterial, and portal venous phase after intravenous contrast administration
British Journal of Radiology · 2026
DOI: 10.1093/bjr/tqaf250 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, 2026. Verfasst von Xiaoyue Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Radiology Department, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing 100050, P.R. China. Hauptthemen laut MEDLINE: Bone Density, Durapatite, Liver Cirrhosis, Contrast Media. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objectives
To access the impact of intravenous contrast on the diagnostic efficacy of abdominal spectral CT-based vertebral hydroxyapatite (HAP) concentration measurement for bone mineral density (BMD) assessment in menopausal women, women undergoing menopausal transition, and men older than 50 years with liver cirrhosis.
Methods
One hundred and seventy-two patients (mean age, 63.78 ± 7.20 years; range, 51-82 years) with liver cirrhosis enrolled in the study. These individuals underwent comprehensive abdominal spectral abdominal spectral CT scans, which included both unenhanced and contrast-enhanced arterial phase (AP) and portal venous phase (VP). Vertebral HAP concentration was quantified in the medullary compartment of vertebral body (L1-L3) using HAP-based material decomposition images. The receiver operating characteristic (ROC) curves were adapted to investigate the diagnostic efficacy of using unenhanced, AP and VP HAP concentrations for evaluating BMD validated by T-scores on dual-energy X-ray absorptiometry.
Results
HAP values were significantly different among the 3 scan phases (all P < .05). By adjusting thresholds, high accuracies were obtained for detecting low bone mass (osteoporosis or osteopenia) with HAP measurements in all scan phases (all areas-under-ROC > 0.9). The data did not reveal a statistically significant disparity between the unenhanced and AP (P = .055) to detect low bone mass. The efficacies for detecting low bone mass had statistically significant reduction with HAP concentrations in VP (P = .012).
Conclusions
Vertebral HAP concentrations increased in AP and VP compared to unenhanced phase. Advances in knowledge Adjusting thresholds higher in contrast-enhanced phases may maintain high detection efficacies for low bone mass.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiology Department, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing 100050, P.R. China.
- GE HealthCare China, Beijing 100176, P.R. China.
ORCID-Profile: Qiang Ma
Zitieren
APA
Cheng, X., Ma, Q., Hou, X., Zhao, C., Yan, Y., Li, J., & Yang, Z. (2026). Diagnostic ability of spectral CT-based vertebral hydroxyapatite concentration for bone mineral density assessment in patients with liver cirrhosis: evaluating in unenhanced, arterial, and portal venous phase after intravenous contrast administration. British Journal of Radiology. https://doi.org/10.1093/bjr/tqaf250
Vancouver
Cheng X, Ma Q, Hou X, Zhao C, Yan Y, Li J, et al. Diagnostic ability of spectral CT-based vertebral hydroxyapatite concentration for bone mineral density assessment in patients with liver cirrhosis: evaluating in unenhanced, arterial, and portal venous phase after intravenous contrast administration. British Journal of Radiology. 2026. doi:10.1093/bjr/tqaf250
BibTeX
@article{Cheng2026,
author = {Cheng, Xiaoyue and Ma, Qiang and Hou, Xinmeng and Zhao, Chenglin and Yan, Yuanyuan and Li, Jianying and Yang, Zhenghan},
title = {Diagnostic ability of spectral CT-based vertebral hydroxyapatite concentration for bone mineral density assessment in patients with liver cirrhosis: evaluating in unenhanced, arterial, and portal venous phase after intravenous contrast administration},
journal = {British Journal of Radiology},
year = {2026},
doi = {10.1093/bjr/tqaf250}
}
EUVIMED